RxDoctor Payments Data

Bahram Khazai, MD

Internal Medicine · Miami, FLNPI 1275789299

Payments from drug & device makers

$25,789in general payments, 2019–2025

Across 138 payments — averaging $186.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$18K
  • Abbott$2K
  • Medtronic$2K
  • Cambridge Interventional LLC$958
  • Abiomed$465
  • Kiniksa Pharmaceuticals International, PLC$355
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$3,62914%
  • Food & beverage$3,52214%
  • Education$9724%
  • Other$17,66769%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,789 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,121,197
Medicare patients
256
Services billed
5,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArcalystRilonacept16$359,492
XareltoRivaroxaban32$38,603
OzempicSemaglutide23$20,706
JardianceEmpagliflozin21$20,659
EntrestoSacubitril/Valsartan16$12,430
FarxigaDapagliflozin Propanediol12$9,606
BrilintaTicagrelor14$6,931
Atorvastatin Calcium246$2,055
Cilostazol65$1,338
ClopidogrelClopidogrel Bisulfate101$1,110
Albuterol Sulfate HfaAlbuterol Sulfate23$908
Potassium Chloride17$732
Metoprolol Succinate67$715
Isosorbide Dinitrate14$629
Losartan Potassium78$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kiniksa Pharmaceuticals International, PLCArcalyst$355$359,49216 claims
Johnson & JohnsonXarelto$16$38,60332 claims
Novo NordiskOzempic$112$20,70623 claims
Boehringer IngelheimJardiance$124$20,65921 claims
AstraZenecaFarxiga, Brilinta$303$16,53726 claims
NovartisEntresto$245$12,43016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →